Suppr超能文献

在配体结合分析生物分析方法验证的分析回收率评估期间调整内源性生物标志物水平的计算

Calculations for Adjusting Endogenous Biomarker Levels During Analytical Recovery Assessments for Ligand-Binding Assay Bioanalytical Method Validation.

作者信息

Marcelletti John F, Evans Cindy L, Saxena Manju, Lopez Adriana E

机构信息

Immunoanalytical Operations, Tandem Labs, Laboratory Corporation of America® Holdings, 13112 Evening Creek Drive South, San Diego, California, 92128, USA,

出版信息

AAPS J. 2015 Jul;17(4):939-47. doi: 10.1208/s12248-015-9756-2. Epub 2015 Apr 23.

Abstract

It is often necessary to adjust for detectable endogenous biomarker levels in spiked validation samples (VS) and in selectivity determinations during bioanalytical method validation for ligand-binding assays (LBA) with a matrix like normal human serum (NHS). Described herein are case studies of biomarker analyses using multiplex LBA which highlight the challenges associated with such adjustments when calculating percent analytical recovery (%AR). The LBA test methods were the Meso Scale Discovery V-PLEX® proinflammatory and cytokine panels with NHS as test matrix. The NHS matrix blank exhibited varied endogenous content of the 20 individual cytokines before spiking, ranging from undetectable to readily quantifiable. Addition and subtraction methods for adjusting endogenous cytokine levels in %AR calculations are both used in the bioanalytical field. The two methods were compared in %AR calculations following spiking and analysis of VS for cytokines having detectable endogenous levels in NHS. Calculations for %AR obtained by subtracting quantifiable endogenous biomarker concentrations from the respective total analytical VS values yielded reproducible and credible conclusions. The addition method, in contrast, yielded %AR conclusions that were frequently unreliable and discordant with values obtained with the subtraction adjustment method. It is shown that subtraction of assay signal attributable to matrix is a feasible alternative when endogenous biomarkers levels are below the limit of quantitation, but above the limit of detection. These analyses confirm that the subtraction method is preferable over that using addition to adjust for detectable endogenous biomarker levels when calculating %AR for biomarker LBA.

摘要

在使用正常人血清(NHS)等基质进行配体结合分析(LBA)的生物分析方法验证过程中,通常需要对加标验证样品(VS)中可检测的内源性生物标志物水平以及选择性测定进行调整。本文描述了使用多重LBA进行生物标志物分析的案例研究,这些研究突出了在计算分析回收率(%AR)时进行此类调整所面临的挑战。LBA测试方法是Meso Scale Discovery V-PLEX®促炎和细胞因子检测板,以NHS作为测试基质。在加标前,NHS基质空白中20种细胞因子的内源性含量各不相同,从不可检测到易于定量。在生物分析领域,%AR计算中调整内源性细胞因子水平的加减法均有使用。在对NHS中内源性水平可检测的细胞因子进行加标和VS分析后,对两种方法在%AR计算中的情况进行了比较。从各自的总分析VS值中减去可定量的内源性生物标志物浓度得到的%AR计算结果得出了可重复且可靠的结论。相比之下,加法得出的%AR结论往往不可靠,且与减法调整法获得的值不一致。结果表明,当内源性生物标志物水平低于定量限但高于检测限时,减去基质所致的测定信号是一种可行的替代方法。这些分析证实,在计算生物标志物LBA的%AR时,减法比加法更适合用于调整可检测的内源性生物标志物水平。

相似文献

4
Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
J Immunol Methods. 2013 Oct 31;396(1-2):1-7. doi: 10.1016/j.jim.2013.07.007. Epub 2013 Aug 6.
5
Analytical performance of a commercial multiplex Luminex-based cytokine panel in the rat.
J Pharmacol Toxicol Methods. 2018 May-Jun;91:43-49. doi: 10.1016/j.vascn.2018.01.005. Epub 2018 Jan 31.
6
Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
J Pharm Biomed Anal. 2011 Jul 15;55(5):869-77. doi: 10.1016/j.jpba.2011.03.033. Epub 2011 Mar 29.
7
Evolution of fit-for-purpose biomarker validations: an LBA perspective.
Bioanalysis. 2018 Jun 1;10(12):905-907. doi: 10.4155/bio-2017-0267. Epub 2018 Jun 20.
9
Clinical biomarker validation.
Bioanalysis. 2018 Jun 1;10(12):957-968. doi: 10.4155/bio-2018-0061. Epub 2018 Jun 20.
10

本文引用的文献

5
Matrix interference in ligand-binding assays: challenge or solution?
Bioanalysis. 2014 Apr;6(8):1029-31. doi: 10.4155/bio.14.92.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验